MedTrace Logo

Ultra-hypofractionated Radiation in Prostate Cancer

NCT03486821 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-05-05

No results posted yet for this study

Summary

The primary objective of this study is to demonstrate that ultra-hypofractionation of prostate cancer does not increase urinary toxicity as defined by the EPIC-26 GU domain patient reported outcome.

Conditions

  • Early Stage Prostate Cancer

Interventions

RADIATION

Hypofractionated Radiation

All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.

Sponsors & Collaborators

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Xinglei Shen, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-22
Primary Completion
2026-03-02
Completion
2026-03-02
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03486821 on ClinicalTrials.gov